[go: up one dir, main page]

NO974680D0 - Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens - Google Patents

Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens

Info

Publication number
NO974680D0
NO974680D0 NO974680A NO974680A NO974680D0 NO 974680 D0 NO974680 D0 NO 974680D0 NO 974680 A NO974680 A NO 974680A NO 974680 A NO974680 A NO 974680A NO 974680 D0 NO974680 D0 NO 974680D0
Authority
NO
Norway
Prior art keywords
impotence
agents
treatment
containing oxide
release nitrogen
Prior art date
Application number
NO974680A
Other languages
English (en)
Other versions
NO974680L (no
Inventor
Larry K Keefer
Joseph E Saavedra
Paul C Doherty
Mark S Hanamoto
Virgil A Place
Original Assignee
Us Health
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Vivus Inc filed Critical Us Health
Publication of NO974680D0 publication Critical patent/NO974680D0/no
Publication of NO974680L publication Critical patent/NO974680L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
NO974680A 1995-04-10 1997-10-10 Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens NO974680L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/419,044 US5910316A (en) 1992-08-24 1995-04-10 Use of nitric oxide-releasing agents to treat impotency
PCT/US1996/004889 WO1996032118A1 (en) 1995-04-10 1996-04-10 Use of nitric oxide-releasing agents to treat impotency

Publications (2)

Publication Number Publication Date
NO974680D0 true NO974680D0 (no) 1997-10-10
NO974680L NO974680L (no) 1997-12-03

Family

ID=23660566

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974680A NO974680L (no) 1995-04-10 1997-10-10 Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens

Country Status (11)

Country Link
US (2) US5910316A (no)
EP (1) EP0820294A1 (no)
JP (1) JPH11508872A (no)
KR (1) KR19980703796A (no)
AU (1) AU5448096A (no)
CA (1) CA2217863A1 (no)
CZ (1) CZ320497A3 (no)
HU (1) HUP9801591A3 (no)
NO (1) NO974680L (no)
PL (1) PL322742A1 (no)
WO (1) WO1996032118A1 (no)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6323211B1 (en) * 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
GB9608408D0 (en) 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
CA2276183C (en) 1996-12-31 2009-06-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
ES2257813T3 (es) * 1997-06-23 2006-08-01 Cellegy Pharmaceuticals, Inc Terapia de microdosis de condiciones vasculares mediante donadores de no.
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
FR2774594A1 (fr) * 1998-02-12 1999-08-13 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
WO2000019992A1 (en) * 1998-10-06 2000-04-13 The University Of Manitoba Method for treating insulin resistance through hepatic nitric oxide
FR2786699B1 (fr) * 1998-12-02 2002-10-04 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US7052711B2 (en) * 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
AU7101600A (en) * 1999-09-02 2001-03-26 Rice University Nitric oxide-producing hydrogel materials
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
IL153956A0 (en) 2000-08-11 2003-07-31 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
WO2002071922A2 (en) * 2001-03-13 2002-09-19 Clemson University Intraurethral device for treating or detecting various diseases or infections of the urinary system
US6558312B2 (en) 2001-03-13 2003-05-06 Clemson University Intraurethral device for incontinence
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US6867194B2 (en) 2001-08-09 2005-03-15 Wayne State University Enzyme activated nitric oxide donors
EP1436018A1 (en) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
JP2005515218A (ja) * 2002-01-11 2005-05-26 ホイットロック，デービッド，アール． アンモニア酸化細菌を含む組成物およびその使用方法
AU2003230715A1 (en) * 2002-03-21 2003-10-08 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
CA2485167A1 (en) * 2002-05-07 2003-11-20 The Government Of The United States Of America Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
ES2406454T3 (es) * 2002-05-10 2013-06-07 University Of Miami Conservación de ARN y morfología en células y tejidos
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
EP1667643A4 (en) * 2003-08-28 2008-03-05 Nitromed Inc NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
BRPI0414813A (pt) * 2003-09-26 2006-11-14 David R Whitlock método para o uso de bactéria que oxidam a amÈnia
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005081752A2 (en) * 2004-02-09 2005-09-09 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
US7968664B2 (en) 2004-09-27 2011-06-28 The United States Of America As Represented By The Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
EP1757278A1 (en) * 2005-08-23 2007-02-28 NOLabs AB Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer
US7709428B2 (en) 2005-02-23 2010-05-04 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
US20060188528A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Spreadable warming lubricant
CA2597463A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
CA2597444A1 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1704876A1 (en) * 2005-03-24 2006-09-27 NOLabs AB Cosmetic treatment, device for performing said treatment and manufacturing method thereof
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2912259C (en) 2005-05-27 2020-04-28 Mark H. Schoenfisch Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2006128742A2 (en) * 2005-06-01 2006-12-07 Nolabs Ab Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide
EP1731176A1 (en) * 2005-06-01 2006-12-13 NOLabs AB Pre-treatment device comprising nitric oxide
CA2613044A1 (en) * 2005-06-20 2007-01-04 Abbeymoor Medical, Inc. Medicament delivery article, accessory & system
EP1915157A4 (en) * 2005-08-02 2010-09-01 Nicox Sa NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
EP1933845A2 (en) * 2005-08-25 2008-06-25 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US20090192128A1 (en) * 2005-10-04 2009-07-30 Nitromed Inc. Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
US7928079B2 (en) * 2005-10-31 2011-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CA2632683A1 (en) * 2005-12-06 2007-06-14 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
CA2647859C (en) * 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US20110190604A1 (en) * 2006-12-22 2011-08-04 Hyde Roderick A Nitric oxide sensors and systems
US20090112197A1 (en) * 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US8770201B2 (en) * 2007-10-26 2014-07-08 Glycobiosciences Inc. Condom with multifunctional coating
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8877508B2 (en) * 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
EP2262478B1 (en) 2008-03-07 2014-11-05 University of Utah Research Foundation Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
WO2010096766A1 (en) 2009-02-23 2010-08-26 Noxilizer, Inc. Device and method for gas sterilization
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
EP2485734B1 (en) * 2009-10-09 2014-07-02 Merck Sharp & Dohme Corp. Diuretics
US20110139163A1 (en) * 2009-12-15 2011-06-16 Hillila David J Vibration apparatus for stimulating paranasal sinuses
KR101024434B1 (ko) * 2009-12-18 2011-03-23 구인옥 음경발기 보조장치
US9265750B1 (en) 2010-02-22 2016-02-23 Gene C. Benckini Apparatus and method for correction of erectile dysfunction
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3173407A1 (en) 2010-06-30 2017-05-31 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
BR112014000178A2 (pt) 2011-07-05 2017-02-07 Novan Inc composições tópicas
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PT2854841T (pt) 2012-06-04 2017-05-15 Diamedica Inc Isoformas de glicosilação da calicreína 1 em tecido humano
CN103622917B (zh) * 2012-08-23 2017-12-29 尼奥克斯(文莱)控股有限公司 基于微囊化亚硝酸盐和酸化水凝胶的延时产生一氧化氮的系统和方法
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
BR112015023349A2 (pt) 2013-03-15 2017-07-18 Ironwood Pharmaceuticals Inc composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
AU2015247710B2 (en) 2014-04-15 2021-09-09 Aobiome Llc Ammonia-oxidizing Nitrosomonas eutropha strain D23
CN105813617B (zh) 2014-08-08 2021-05-28 诺万公司 局部用组合物和使用所述组合物的方法
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
WO2016044447A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3423100A4 (en) 2016-03-02 2019-10-16 Novan, Inc. COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF
EP3442502A4 (en) 2016-04-13 2019-11-06 Novan, Inc. COMPOSITIONS, SYSTEMS, KITS AND METHODS FOR TREATING INFECTIONS
BR112019000290B1 (pt) 2016-07-07 2022-10-18 Cyclerion Therapeutics, Inc Prófármacos de fósforo dos estimuladores da sgc
KR20190025989A (ko) 2016-07-07 2019-03-12 아이언우드 파마슈티컬스, 인코포레이티드 sGC 자극제의 고체 형태
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
AU2018247167B2 (en) 2017-03-28 2024-05-16 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2019099525A1 (en) 2017-11-15 2019-05-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
KR102088809B1 (ko) * 2018-06-20 2020-03-13 연세대학교 산학협력단 산화질소 전달체 및 그 제조방법
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法
WO2021158941A1 (en) 2020-02-07 2021-08-12 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE211789C (no)
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
NL145762B (nl) * 1970-05-27 1975-05-15 Sandoz Ag Werkwijze ter bereiding van een farmaceutisch preparaat met hypotensieve/antihypertensieve werking, alsmede gevormd preparaat.
US3826832A (en) * 1970-06-08 1974-07-30 Sandoz Ag N-substituted amino-n-nitro-amino-acetonitriles as anti-anginal agents
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4265714A (en) * 1980-03-24 1981-05-05 General Electric Company Gas sensing and measuring device and process using catalytic graphite sensing electrode
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
DD211789A1 (de) * 1982-08-25 1984-07-25 Adw Ddr Verfahren zur herstellung von polyhydroxypolymerestern, insbesondere von celluloseestern
US4638079A (en) * 1985-01-17 1987-01-20 Mallinckrodt, Inc. Inhibiting polymerization of ethylenically unsaturated monomers
US4708854A (en) * 1986-03-10 1987-11-24 The Dow Chemical Company Process for the removal of NO from fluid streams using a water-soluble polymeric chelate of a polyvalent metal
US4829991A (en) * 1987-01-06 1989-05-16 Medical Engineering Corp. Method and device for stimulating an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
JPS63260971A (ja) * 1987-04-20 1988-10-27 Hitachi Chem Co Ltd 放射線硬化型粘着剤組成物
US4952289A (en) * 1988-05-09 1990-08-28 Aquanautics Corporation Macrocyclic amine complexes for ligand extraction and generation
US5094815A (en) * 1988-05-18 1992-03-10 Cornell Research Foundation, Inc. Photolytic interface for HPLC-chemiluminescence detection of non volatile N-nitroso compounds
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US4921683A (en) * 1989-06-20 1990-05-01 The Dow Chemical Company Nitric oxide abatement with polymeric cobalt(III) chelates
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
FR2653337B1 (fr) * 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5087671A (en) * 1990-06-25 1992-02-11 The Curators Of The University Of Missouri Polymers for scavenging nitrosating agents
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5087631A (en) * 1990-12-18 1992-02-11 Glaxo Inc. Oxathi(SIV)azol-5-one compounds
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
ES2134804T3 (es) * 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
WO1993007114A1 (en) * 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
JP3989949B2 (ja) * 1992-02-07 2007-10-10 バソジェン アイルランド リミテッド 血中の酸化窒素濃度を増加させる方法
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
CA2106105C (en) * 1993-09-14 2008-03-18 Larry K. Keefer Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
DE69425331D1 (de) * 1993-10-08 2000-08-24 Us Health Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
US5482925A (en) * 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Also Published As

Publication number Publication date
PL322742A1 (en) 1998-02-16
KR19980703796A (ko) 1998-12-05
HUP9801591A3 (en) 2000-06-28
AU5448096A (en) 1996-10-30
NO974680L (no) 1997-12-03
US5910316A (en) 1999-06-08
EP0820294A1 (en) 1998-01-28
HUP9801591A2 (hu) 1999-02-01
CA2217863A1 (en) 1996-10-17
US6290981B1 (en) 2001-09-18
JPH11508872A (ja) 1999-08-03
CZ320497A3 (cs) 1998-05-13
WO1996032118A1 (en) 1996-10-17

Similar Documents

Publication Publication Date Title
NO974680D0 (no) Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens
ITRM940150A0 (it) Procedimento per il trattamento di acque di scarico fortemente colorate.
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
AP9801414A0 (en) Combination effective for the treatment of impotence
DK0880892T3 (da) Midler med reguleret frigivelse
AP2000001796A0 (en) The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
NO975545D0 (no) Cellelinje som produserer analgetiske forbindelser for behandling av smerte
DE59409547D1 (de) Trennmittel
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO982562D0 (no) Sammensetning for behandling av smerte
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
HU9502697D0 (en) Drogs for the treatment of retrovirus infections
NO994140D0 (no) Farmasöytisk sammensetning for den programerte frigivelse av deksfenfluramin
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
DE69528372D1 (de) Orale behandlung
NO963856L (no) Peptider som inhiberer frigjöringen av pepsin
ZA986324B (en) Composition for the treatment of immunodeficiency disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application